Prophase Labs, INC 10-Q quarterly reports

ProPhase Labs files an amended 10-Q report for Q1 2026, restating financial statements due to identified errors in revenue, cost of goods sold, and deferred revenue.

ProPhase Labs amends its Q1 2026 10-Q filing due to auditor review completion, reporting a net loss and significant liquidity challenges.

ProPhase Labs reports a significant decrease in revenue for Q1 2026 compared to the prior year, primarily due to a decline in consumer product sales, while continuing to address substantial going concern issues.

ProPhase Labs reported a net loss of $6.8 million for Q3 2025, driven by declining consumer product revenue and increased interest expense, while advancing its BE-Smart diagnostic test and facing a Nasdaq delisting warning.

ProPhase Labs reported a narrower net loss and significantly improved gross margins in Q2 2025, driven by strategic divestitures and a focus on higher-margin consumer products, despite a decline in overall revenue.

ProPhase Labs reports a net income of $3.966 million for Q1 2025, driven by the sale of Pharmaloz Manufacturing, despite a decrease in overall revenue compared to Q1 2024.

ProPhase Labs experienced a significant revenue decrease in Q3 2024, primarily due to reduced diagnostic testing demand, while also highlighting ongoing efforts in genomics and drug development.

ProPhase Labs experienced a significant decrease in revenue in the second quarter of 2024, primarily due to a sharp decline in diagnostic testing services, while also seeing a decrease in consumer product sales.

ProPhase Labs experienced a significant decrease in revenue during the first quarter of 2024, primarily due to reduced demand for COVID-19 diagnostic testing.